Subscribe for the newsletter
Sign in
Articles
Expert Interviews
Roundtable
Press Releases
Videos
The Road To Series
Market Research
Directory
More
Discovery
Small Molecules
Biologics
Advanced Therapies
Manufacturing
Supply Chain
Clinical Trials
Technologies
Financing
Gilead Sciences, Inc.
Sort By
Newest First
1 / 2
FDA Approval
FDA Approves Trodelvy®, the First Treatment for Metastatic Triple-Negative Breast Cancer Shown to Improve Progression-Free Survival and Overall Survival
PR-M04-21-007
Apr 09, 2021
ProteoNic
Licensing
ProteoNic Announces Licensing of its 2G UNic™ Technology Platform for Production of Biologics to Gilead Sciences
ProteoNic
PR-M11-20-004
Nov 05, 2020
Gilead Sciences
M&A
Gilead Sciences to Acquire Immunomedics
Gilead Sciences
PR-M09-20-NI-18
Sep 15, 2020
Gilead Sciences
COVID-19
Gilead’s Remdesivir Receives FDA Emergency Use Authorization for the Treatment of Patients With Moderate COVID-19
Gilead Sciences
PR-M08-20-NI-48
Aug 31, 2020
Gilead Sciences
Strategic Partnership
Gilead Sciences and Arcus Biosciences Complete Closing of Their 10-Year Partnership to Co-Develop and Co-Commercialize Next-Generation Cancer Immunotherapies
Gilead Sciences
PR-M07-20-NI-021
Jul 15, 2020
Gilead Sciences
COVID-19 Trial Data
Gilead Presents Additional Data on Investigational Antiviral Remdesivir for the Treatment of COVID-19
Gilead Sciences
PR-M07-20-NI-015
Jul 10, 2020
Gilead Sciences
M&A
Gilead Sciences Secures Exclusive Option to Acquire Pionyr Immunotherapeutics
Gilead Sciences
PR-M06-20-NI-028
Jun 23, 2020
Gilead Sciences
Partnership
Gilead Sciences and Arcus Biosciences Establish 10-year Partnership to Co-develop and Co-commercialize Next-generation Cancer Immunotherapies
Gilead Sciences
PR-M05-20-NI-041
May 28, 2020
Mylan
COVID-19 Treatment
Mylan to Supply Investigational Antiviral Remdesivir for the Potential Treatment of COVID-19
Mylan
PR-M05-20-NI-018
May 14, 2020
Gilead Sciences
Gilead Sciences Statement on Access to Remdesivir Outside of Clinical Trials
Gilead Sciences
PR-M04-20-NI-003
Apr 02, 2020
Gilead Sciences
M&A
Gilead to Acquire Forty Seven for $4.9 Billion
Gilead Sciences
PR-M03-20-NI-003
Mar 02, 2020
Gilead Sciences
Coronavirus
Gilead Sciences Initiates Two Phase 3 Studies of Investigational Antiviral Remdesivir for the Treatment of COVID-19
Gilead Sciences
PR-M02-20-NI-037
Feb 27, 2020
Gilead Sciences
Coronavirus
Gilead Sciences Begins Trial on Treatment for Coronavirus (2019-nCoV)
Gilead Sciences
PR-M02-20-NI-003
Feb 04, 2020
Licensing
Gilead Licenses Antiviral Candidates from Novartis
Nice Insight
PAO-M08-19-NI-019
Aug 15, 2019
Gilead Sciences
Collaboration
Gilead and Galapagos Enter Into Transformative Research and Development Collaboration
Gilead Sciences
PR-M07-19-NI-046
Jul 18, 2019
Gilead Sciences
Capacity Expansion
Kite Announces Plans to Bolster Industry-Leading Cell Therapy Manufacturing Capabilities With New Viral Vector Facility
Gilead Sciences
PR-M07-19-NI-043
Jul 17, 2019
AbCellera Biologics Inc.
Announcement
AbCellera Announces Therapeutic Antibody Discovery Collaboration with Gilead in Infectious Disease
AbCellera Biologics Inc.
PR-M06-19-NI-017
Jun 14, 2019
Gilead Sciences
Appointment
Gilead Sciences Appoints Johanna Mercier as Chief Commercial Officer
Gilead Sciences
PR-M05-19-NI-081
May 29, 2019
Gilead Sciences
HIV
Gilead Sciences to Provide Free Truvada for PrEP® to Support U.S. Initiative to End the HIV Epidemic
Gilead Sciences
PR-M05-19-NI-038
May 14, 2019
Leadership
Changes Coming to Gilead Under New Top Exec
Pharma's Almanac
PAO-M05-19-NI-016
May 10, 2019
1 / 2
